LON:HEMO Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis → Elon Musk’s Controversial New Project: “Apollo” (From InvestorPlace) (Ad) Free HEMO Stock Alerts GBX 1.63 +0.01 (+0.31%) (As of 07:47 AM ET) Add Compare Share Share Today's Range 1.63▼ 1.7050-Day Range 1.57▼ 3.4652-Week Range 1.10▼ 7.13Volume12.81 million shsAverage Volume14.05 million shsMarket Capitalization£21.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Hemogenyx Pharmaceuticals alerts: Email Address Ad InvestorPlaceElon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake. About Hemogenyx Pharmaceuticals Stock (LON:HEMO)Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.Read More HEMO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HEMO Stock News HeadlinesApril 15, 2024 | msn.comSMALL CAP IDEA: Why investors should add Hemogenyx Pharmaceuticals to their watchlistMarch 30, 2024 | msn.comCompare with Oxurion NV (0G99)April 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 28, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Total Voting RightsMarch 13, 2024 | proactiveinvestors.comAlbo unveils ambitious $4 billion plan to overhaul remote housing in the Northern TerritoryMarch 12, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals discusses successful £3.5M capital raise as it advances HEMO-CAR-T programFebruary 29, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Placing to Raise US$4.2 millionFebruary 21, 2024 | lse.co.ukLondon pre-open: Stocks to nudge up; HSBC in focusApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.February 20, 2024 | finance.yahoo.comLung Cancer Research Foundation and American Lung Cancer Screening Initiative Join Forces for "Plus One" CampaignFebruary 20, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platformFebruary 16, 2024 | lse.co.ukHemogenyx shares rise on potential for CBR to treat brain diseasesFebruary 16, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces CBR Brain DeliveryFebruary 14, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces CBR Intranasal DeliveryFebruary 9, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-TFebruary 2, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces the Approval and Issuance of U.S. Conditioning PatentJanuary 16, 2024 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical HoldJanuary 8, 2024 | lse.co.ukHemogenyx Pharmaceuticals completes process qualification runNovember 28, 2023 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Placing to Raise £534,375November 27, 2023 | lse.co.ukHemogenyx shares up as says CBR platform a potential cancer treatmentNovember 27, 2023 | marketwatch.comHemoGenyx Says CBR Platform Could Potentially Be Used for Cancer TreatmentNovember 27, 2023 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces CBR Expanded to Treatment of CancerNovember 15, 2023 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Lentivirus Re-manufacturing CompletedSeptember 28, 2023 | lse.co.ukEARNINGS: Dar Global profit multiplies, Hemogenyx loss widensSeptember 18, 2023 | seekingalpha.comPrevail Partners to invest in Hemogenyx PharmaceuticalsSeptember 18, 2023 | marketwatch.comHemogenyx Stock Rises on Premium Share SubscriptionSeptember 14, 2023 | marketwatch.comHemogenyx Pharmaceuticals Says FDA Accepted Plans to Address Leukemia Treatment ConcernsSee More Headlines Receive HEMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/30/2020Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:HEMO Previous SymbolLON:SILF CUSIPN/A CIKN/A Websilverfalconplc.com Phone44 79 0917 7311FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-7,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-136.44% Return on Assets-58.66% Debt Debt-to-Equity Ratio89.95 Current Ratio4.07 Quick Ratio6.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,340,000,000Free FloatN/AMarket Cap£22.30 million OptionableNot Optionable Beta3.06 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Vladislav Sandler Ph.D. (Age 59)Co-Founder, CEO & Director Comp: $282kMs. Alexis M. Sandler J.D. (Age 48)Independent Co-Founder & Non-Executive Director Comp: $57kDr. Koen Van Besien M.D.Ph.D., Clinical Advisor & Medical DirectorKey CompetitorsDestiny PharmaLON:DESTC4X DiscoveryLON:C4XDOKYO PharmaLON:OKYOAorTech InternationalLON:AORSareumLON:SARView All Competitors HEMO Stock Analysis - Frequently Asked Questions How have HEMO shares performed in 2024? Hemogenyx Pharmaceuticals' stock was trading at GBX 2.30 at the start of the year. Since then, HEMO stock has decreased by 27.7% and is now trading at GBX 1.66. View the best growth stocks for 2024 here. How were Hemogenyx Pharmaceuticals' earnings last quarter? Hemogenyx Pharmaceuticals Plc (LON:HEMO) issued its quarterly earnings data on Wednesday, September, 30th. The company reported ($0.20) earnings per share for the quarter. What other stocks do shareholders of Hemogenyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hemogenyx Pharmaceuticals investors own include Avaya (AVYA), Baidu (BIDU), Corbus Pharmaceuticals (CRBP), Curaleaf (CURLF), Heat Biologics (HTBX), Incyte (INCY), InMode (INMD), Intuitive Surgical (ISRG) and Remark (MARK). How do I buy shares of Hemogenyx Pharmaceuticals? Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:HEMO) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm PressThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
